Faculty Opinions recommendation of Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Author(s):  
Randy Gascoyne
2013 ◽  
Vol 110 (45) ◽  
pp. 18250-18255 ◽  
Author(s):  
S. Bea ◽  
R. Valdes-Mas ◽  
A. Navarro ◽  
I. Salaverria ◽  
D. Martin-Garcia ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4270-4270
Author(s):  
Ismael Buño ◽  
Paola Nava ◽  
Angela Alvarez-Doval ◽  
Ainhoa Simon ◽  
Gonzalez-Pardo Gema ◽  
...  

Abstract Detection of specific chromosomal abnormalities is essential in the diagnosis of several lympholiferative disorders. However, conventional cytogenetic studies are not frequently carried out from biopsies as it is in bone marrow (BM) specimens. On the contrary, FISH is usually performed on paraffin embedded tissue, an alternative with potential technical nuances both in its application and its interpretation. In our experience, FISH on tissue imprints is the ideal alternative to overcome these problems. In the present study, 46 tissue imprints and 17 BM smears from 43 patients with lymphomas were selected to investigate the presence of t(14;18)(q32;q21), t(11;14)(q13;q32), t(8;14)(q24;q32) and t(3;var)(q27;var). Representativity of the samples was assured prior to FISH by rapid May-Grümwald staining (Diff-Quick, QCA, Spain). Twenty imprints from reactive palatine tonsils and adenoids were used as negative controls. FISH was performed with specific dual-color dual-fusion FISH (D-FISH) probes for the first 3 translocations and a dual-color break-apart FISH probe for t(3;var)(q27;var) following the instructions of the probes supplier (Vysis, Inc). All except one sample (a BM smear stored at room temperature over 9 years), rendered satisfactory FISH hybridizations. In any case, all 43 patients could be successfully studied by FISH (the case referred above in which FISH failed in a first attempt was successfully analyzed using a different sample). The results supported the suspected diagnosis of follicular lymphoma in 22 patients, mantle cell lymphoma in 12 patients, large B-cell lymphoma in 5 patients, marginal zone lymphoma in 2 patients and B chronic lymphocytic leukemia in 2 patients. In one case, the observation of t(11;14) by FISH allowed to reclassify the case from follicular to mantle cell lymphoma and also to demonstrate clonal evolution by studying sequential tissue imprints stored for more than 6 years. Negative results also aided in the assignment of patients to proper diagnostic categories. FISH performed on tissue imprints and BM smears constitutes an optimal strategy for retrospective and prospective investigation of chromosomal abnormalities in lymphomas. Tissue imprints and BM smears conventionally stored at room temperature even for long periods of time can be safely used and sent by ordinary mail without special considerations for this purpose. Based on our experience we recommend to perform and routinely store tissue imprints whenever fresh tissue is available.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4094-4094 ◽  
Author(s):  
Atish Ranjan Mohanty ◽  
Natalie Sandoval ◽  
Manasi Das ◽  
Hesham M. Amin ◽  
Guido Marcucci ◽  
...  

Abstract Mantle cell lymphoma (MCL) represents 6-8% of non-Hodgkin's lymphoma with a median survival of 3-5 years. CyclinD1 (CCND1) chromosomal translocation t(11;14) is the hallmark of this neoplasm, which leads to its deregulated expression. Recent knock down studies of CCND1 in MCL have shown that its role is not only limited to promote cell cycle progression but also for maintaining genomic stability. Knock down of CCND1 results in increased DNA damage in MCL cells and makes them more susceptible to chemotherapy. However, CCND1 is not only prone to frequent translocation but also to somatic mutations. Genomic studies have identified recurring somatic mutations in the coding region of CCND1 in approximately 30% of MCL cases. The hot spot of these mutations is concentrated in exon 1 of CCND1. However, the functional consequence of these mutations is not known. We generated the most common CCND1 mutations (E36K, Y44D or C47S) by site directed mutagenesis and overexpressed these mutants in JEKO-1, UPN-1 or Z-138 MCL cell lines. Here, we show that these single mutations, as compared to the wild type (WT), increased CCND1 protein levels in MCL cell lines and primary tumors. Mechanistically, mutations Y44D or C47S increase the stability of CCND1 protein through attenuation of threonine-286 phosphorylation, which is a prerequisite for export of CCND1 from the nucleus to the cytoplasm, followed by proteolysis through the ubiquitin-proteasome pathway. But the two mutants have stronger affinity to interact with the threonine-286 phosphorylating enzyme glycogen synthase kinase 3 beta ,whereas interaction with cyclin-dependent kinase 4 remains unaffected. Furthermore we observed that these two mutants are preferentially localized in the nucleus compared to WT, as determined by cell fractionation and immunofluorescence assays. In order to understand the relevance of stable CCND1 protein in MCL, we studied the response of WT or mutant CCND1-expressing MCL cell lines to ibrutinib, an FDA- approved Bruton tyrosine kinase inhibitor used for MCL treatment. We observed that forced expression of WT or mutant CCND1 increased the resistance of JEKO-1 cells to ibrutinib. The Y44D mutation sustained the resistance to ibrutinib at supraphysiologic concentrations (5-10 μM). Furthermore, primary MCL tumors with CCND1 mutations expressed a more stable protein and were resistant to ibrutinib than WT cases. These findings uncover new mechanisms for MCL cells to increase CCND1 protein level through somatic mutations, which may provide a survival advantage to the lymphoma cells in developing resistance against the emerging ibrutinib therapy. Disclosures Pillai: Trillium Therapeutics: Research Funding. Pham:Vyripharm Biopharmaceuticals: Research Funding.


2019 ◽  
Vol 5 (6) ◽  
pp. a004259 ◽  
Author(s):  
Hammad Tashkandi ◽  
Kseniya Petrova-Drus ◽  
Connie Lee Batlevi ◽  
Maria E. Arcila ◽  
Mikhail Roshal ◽  
...  

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5217-5217
Author(s):  
Changying Jiang ◽  
Shaojun Zhang ◽  
Yuanxin Wang ◽  
Rongjia Zhang ◽  
Yang Liu ◽  
...  

Introduction: Both inter- and intra-tumoral heterogeneity are obstacles to improving oncology clinical outcomes. Mantle cell lymphoma (MCL) is an extremely heterogeneous disease in clinical, pathological, genetic, and transcriptomic profiling. Furthermore, MCL patients frequently develop therapeutic resistance after frontline therapies. In this study, we performed longitudinal transcriptomic analysis on primary patient MCL specimens at single-cell resolution, aiming to understand the dynamic and complex cellular and molecular changes underlying therapeutic resistance and identify potential targets to overcome dual resistance to ibrutinib and venetoclax. Methods: Sequential single-cell transcriptome sequencing (scRNA-seq) was performed on patient specimens collected during the course of treatment(s) from 5 MCL patients (3 ibrutinib responders and 2 ibrutinib-venetoclax non-responders). Integrative computational approaches were employed to characterize the cellular and molecular basis of therapeutic resistance and clonal evolution. An orthotopic PDX model derived from one of the non-responders was established and used to validate the novel findings and to investigate the in vivo efficacies of multiple novel potential targets. Results: The 3 ibrutinib responders and 2 ibrutinib-venetoclax non-responders were highly heterogeneous in clinical and pathological profiling. To dissect the inter- and intra-tumor heterogeneity underlying the therapeutic resistance, we performed sequential scRNA-seq analysis of 21 specimens collected at baseline, during treatment, and/or at disease remission/progression. The scRNA-seq analysis revealed a high degree of inter- and intra-tumor heterogeneity with distinct cellular and transcriptomic profiling within and across ibrutinib-responders and ibrutinib-venetoclax non-responders. Unsupervised pathway enrichment analysis identified more than 15 cancer hallmarks significantly upregulated in ibrutinib-venetoclax non-responders. We tracked the clinical ibrutinib-induced lymphocytosis at a single-cell transcriptomic level in ibrutinib responders and disease-progression-associated clonal evolution in non-responders. Multiple actionable targets were identified, and targeting these showed effective anti-MCL activity in the orthotopic PDX model derived from one of the ibrutinib-venetoclax non-responders. Conclusions: This study demonstrates the potential of longitudinal single-cell transcriptomic analysis to reveal the molecular mechanisms underlying tumor heterogeneity, clonal evolution, disease progress, and therapeutic resistance, and to identify potential novel targets to circumvent therapeutic resistance in mantle cell lymphoma and other diseases. Disclosures Wang: Pharmacyclics: Honoraria, Research Funding; Juno Therapeutics: Research Funding; Celgene: Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Guidepoint Global: Consultancy; Kite Pharma: Consultancy, Research Funding; Acerta Pharma: Consultancy, Research Funding; MoreHealth: Consultancy, Equity Ownership; Loxo Oncology: Research Funding; VelosBio: Research Funding; BioInvent: Consultancy, Research Funding; Dava Oncology: Honoraria; Aviara: Research Funding.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 347-347
Author(s):  
Jenny Zhang ◽  
Dereje Jima ◽  
Qingquan Liu ◽  
Andrea Moffitt ◽  
Magdalena Czader ◽  
...  

Abstract Mantle cell lymphoma is an uncommon form of non Hodgkin lymphoma that is characterized by poor responsiveness to chemotherapy and a high rate of mortality. While translocation of CCND1 is a defining feature of the disease, the role of collaborating somatic mutations that contribute to mantle cell lymphoma remains to be better defined. In this study, we sought to better understand the patterns of mutations that occur in tumors derived from closely related stages of B cell differentiation. We began by performing exome sequencing in 55 cases of mantle cell lymphoma to broadly identify the mutational landscape of the disease. We then defined the chromatin structure of the normal counterpart B cells (naïve and germinal center B cells respectively) for mantle cell lymphoma and Burkitt lymphoma by profiling their epigenetic markers using chromatin immunoprecipitation followed by sequencing (ChIP-seq). We found that the somatic mutational profiles of mantle cell lymphoma and Burkitt lymphomas overlapped strongly with areas of open chromatin in their normal counterpart B cells, identifying B cell developmental lineage as a factor in the acquisition of somatic mutations. We identified somatic mutations affecting 311 genes in at least one tumor/germline pair among MCL cases. These variants were not present in publicly available data from normal controls including dbSNP135, the 1000 Genomes Project and available exome sequencing data from healthy individuals without lymphoma. We further required each of the identified genes to have a minimum of two rare and predicted functional variants for genes already in COSMIC, and three such variants in novel genes. The most frequently mutated genes in mantle cell lymphoma were ATM (41.9%), CCND1 (14%) and TP53 (18.6%). Other frequently mutated genes included known oncogenes and tumor suppressor genes such as RB1, SMARCA4, and APC. Our data also implicated a number of genes not previously associated with mantle cell lymphoma, including POT1, FAT4 and ROBO2. Silencing mutations (frameshift and nonsense mutations) comprised a sizeable fraction of the genetic events in ATM, MLL3, RB1 and ROBO2, suggesting that those alterations result in a loss of function in mantle cell lymphoma. To better understand the genetic differences between common non Hodgkin lymphomas, we examined exome sequencing data that we and others have generated from Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL). We identified all genes that were mutated in roughly 10% of at least one lymphoma type and differentially mutated relative to at least one of the other lymphoma types (P<0.05, Fisher’s exact test). We found a number of genes that were predominantly mutated in each type. Mutations in ATM, CCND1, POT1 and RB1 occurred mostly in mantle cell lymphoma. Mutations in ID3 and MYC occurred predominantly in Burkitt lymphoma. Mutations in PIM1, FRMPD1 and CREBBP occurred mostly in DLBCLs. A number of genes had overlapping patterns of mutations between two or more of the diseases, including MLL3, TP53, ARID1A and SETD2. We sought to define the relationship between the epigenetically determined chromatin state of normal B cells and the lymphomas that are thought to arise from them. We began by FACS-sorting normal naïve B cells, germinal center B cells and memory B cells from otherwise normal individuals undergoing tonsillectomy. We profiled the chromatin structure and epigenetic state of the normal B cells through chIP-seq on 6 different markers: H3K4me1, H3K4me3, H3Ac, H3K27me3, H4K36me3, and CTCF. Using these epigenetic markers, differences in open chromatin between naïve B cells and germinal center B cells were computed for genes that were differentially mutated in mantle cell lymphoma and Burkitt lymphoma. We found that difference in gene mutation frequency between mantle cell lymphoma and Burkitt lymphoma is highly associated with differences in open chromatin in their corresponding cells of origin (P=0.02, Fisher's exact test). Our work demonstrates that the sequencing of relatively uncommon tumors such as mantle cell lymphoma and Burkitt lymphoma afford not only new insights into the genetics of these tumors, but also allow us to better examine the broader effects of lineage and epigenetic alterations in cancer. This work thus provides an important starting point for understanding the genetic diversity of mantle cell lymphomas and the interplay between genetic and epigenetic alterations in cancer. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document